Literature DB >> 26653933

Impact of ventricular assist device placement on longitudinal renal function in children with end-stage heart failure.

Lindsay J May1, Maria E Montez-Rath2, Justin Yeh3, David M Axelrod4, Sharon Chen4, Katsuhide Maeda5, Christopher S D Almond4, David N Rosenthal4, Seth A Hollander4, Scott M Sutherland6.   

Abstract

BACKGROUND: Although ventricular assist devices (VADs) restore hemodynamics in those with heart failure, reversibility of end-organ dysfunction with VAD support is not well characterized. Renal function often improves in adults after VAD placement, but this has not been comprehensively explored in children.
METHODS: Sixty-three children on VAD support were studied. Acute kidney injury (AKI) was defined by Kidney Disease: Improving Global Outcomes criteria. Estimated glomerular filtration rate (eGFR) was determined by the Schwartz method. Generalized linear mixed-effects models compared the pre-VAD and post-VAD eGFR for the cohort and sub-groups with and without pre-VAD renal dysfunction (pre-VAD eGFR < 90 ml/min/1.73 m(2)).
RESULTS: The pre-VAD eGFR across the cohort was 84.0 ml/min/1.73 m(2) (interquartile range [IQR] 62.3-122.7), and 55.6% (34 of 63) had pre-VAD renal dysfunction. AKI affected 60.3% (38 of 63), with similar rates in those with and without pre-existing renal dysfunction. Within the cohort, the nadir eGFR occurred 1 day post-operatively (62.9 ml/min/1.73 m(2); IQR, 51.2-88.9 ml/min/1.73 m(2); p < 0.001). By Day 5, however, the eGFR exceeded the baseline (99.0 ml/min/1.73 m(2); IQR, 59.3-146.7 ml/min/1.73 m(2); p = 0.03) and remained significantly higher through the first post-operative week. After adjusting for age, gender, and AKI, the eGFR continued to increase throughout the entire 180-day study period (β = 0.0025; 95% confidence interval, 0.0015-0.0036; p < 0.001). Patients with pre-VAD renal dysfunction experienced the greatest improvement in the eGFR (β = 0.0051 vs β = 0.0013, p < 0.001).
CONCLUSIONS: Renal dysfunction is prevalent in children with heart failure undergoing VAD placement. Although peri-operative AKI is common, renal function improves substantially in the first post-operative week and for months thereafter. This is particularly pronounced in those with pre-VAD renal impairment, suggesting that VADs may facilitate recovery and maintenance of kidney function in children with advanced heart failure.
Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  children; end-organ dysfunction; end-stage heart failure; renal function; ventricular assist device

Mesh:

Year:  2015        PMID: 26653933     DOI: 10.1016/j.healun.2015.10.039

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  4 in total

Review 1.  Mechanical circulatory support in children: past, present and future.

Authors:  Svetlana B Shugh; Kyle W Riggs; David L S Morales
Journal:  Transl Pediatr       Date:  2019-10

2.  Hemodynamic Predictors of Renal Function After Pediatric Left Ventricular Assist Device Implantation.

Authors:  Chiu-Yu Chen; Maria E Montez-Rath; Lindsay J May; Katsuhide Maeda; Seth A Hollander; David N Rosenthal; Catherine D Krawczeski; Scott M Sutherland
Journal:  ASAIO J       Date:  2021-12-01       Impact factor: 2.872

3.  Heart-kidney listing is better than isolated heart listing for pediatric heart transplant candidates with significant renal insufficiency.

Authors:  Alia Dani; Nina Price; Karthik Thangappan; Thomas D Ryan; David K Hooper; David S Cooper; David G Lehenbauer; Clifford Chin; Farhan Zafar; David L S Morales
Journal:  J Thorac Cardiovasc Surg       Date:  2022-03-01       Impact factor: 6.439

Review 4.  Kidney replacement therapy in pediatric patients on mechanical circulatory support: challenges for the pediatric nephrologist.

Authors:  Alexandra Idrovo; Natasha Afonso; Jack Price; Sebastian Tume; Ayse Akcan-Arikan
Journal:  Pediatr Nephrol       Date:  2020-05-28       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.